Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - A single-center experience

Onkologie

Volumn 31, Issue 1-2, 2008, Pages 11-16

  Ebeling, P ^a   Eisele, L ^a   Schuett, P ^a   Bauer, S ^a   Schuette, J ^b   Moritz, T ^a   Seeber, S ^a   Flasshove, M ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MARIEN HOSPITAL DÜSSELDORF   (Germany)

^c Krankenhaus Duren gem GmbH   (Germany)

Author keywords

Docetaxel; Gemcitabine; Leiomyosarcoma; Soft tissue sarcoma

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DACARBACINE; DOCETAXEL; DOXORUBICIN; EXATECAN; GEMCITABINE; IFOSFAMIDE; IMATINIB; TROFOSFAMIDE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALVEOLAR SOFT PART SARCOMA; ANEMIA; ANGIOSARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; EMBRYONAL RHABDOMYOSARCOMA; EPIDERMIOLYSIS; EPITHELIOID SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NERVE SHEATH TUMOR; NEUTROPENIA; PERIANAL ABSCESS; PNEUMONIA; RETROSPECTIVE STUDY; SKIN DEFECT; SOFT TISSUE METASTASIS; SOFT TISSUE SARCOMA; SPINDLE CELL SARCOMA; STOMATITIS; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 39149100922     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111756     Document Type: Article

References (39)

1. Buesa JM, Mouridsen HT, van Oosterom AT, Verweij J, Wagener T, Steward W, Poveda A, Vestlev PM, Thomas D, Sylvester R: High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991;2(4):307-9.
2. Fiegl M, Schlemmer M, Wendtner CM, Abdel-Rahman S, Fahn W, Issels RD: Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. Int J Hyperthermia 2004;20(6):661-70.
3. Gullu I, Yalcin S, Tekuzman G, Barista I, Alkis N, Celik I, Zengin N, Guler N, Kars A, Baltali E, et al.: High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas. Cancer Invest 1996;14(3):239-42.
4. Bauer S, Hartmann JT: Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors. Crit Rev Oncol Hematol 2006;60(2):112-30.
5. Losa R, Fra J, Lopez-Pousa A, Sierra M, Goitia A, Una E, Nadal R, Del Muro JG, Gion M, Maurel J, Escudero P, Esteban E, Buesa JM: Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemother Pharmacol 2007;59(2):251-9.
6. Woll PJ, Judson I, Lee SM, Rodenhuis S, Nielsen OS, Buesa JM, Lorigan PC, Leyvraz S, Hermans C, van Glabbeke M, Verweij J: Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999;35(3):410-2.
7. Fayette J, Coquard IR, Alberti L, Boyle H, Meeus P, Decouvelaere AV, Thiesse P, Sunyach MP, Ranchere D, Blay JY: ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006;18(4):347-53.
8. Fayette J, Coquard IR, Alberti L, Ranchere D, Boyle H, Blay JY: ET-743: a novel agent with activity in soft tissue sarcomas. Oncologist 2005;10(10):827-32.
9. Grosso G, Demetri D, Blay JY, Judson I, LeCesne A, Spreafico C, Jimeno J, Pilotti S, D'Incalci M, Casali PG: Patterns of tumor response to trabectedin (ET743) in myxoid liposarcoma. J Clin Oncol 2006;24(18S):522s(abstr).
10. Amodio A, Carpano S, Manfredi C, Del Monte G, Di Lauro L, Gionfra T, Conti F, Paoletti G, Lopez M: Gemcitabine in advanced stage soft tissue sarcoma: a phase II study (article in Italian). Clin Ter 1999;150(1):17-20.
11. Bauer S, Hartung J, Gauler T, Gocke P, Flasshove M, Nowrousian M, Bojko P, Hense J, Seeber S, Schutte J: Gemcitabine-containing chemotherapy in the treatment of patients with advanced soft tissue sarcoma. Tumordiagn Ther 2002;23:219-24.
12. Bauer S, Seeber S, Schutte J: Gemcitabine in the treatment of soft tissue sarcomas. Onkologie 2004;27(2):180-6.
13. Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C: An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 2006;24(3):249-53.
14. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000;45(2):177-81.
15. Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH: Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003;97(8):1969-73.
16. Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS: Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38(4):556-9.
17. Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A: Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 2006;29(1):59-61.
18. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19(15):3483-9.
19. van Hoesel QG, Verweij J, Catimel G, Clavel M, Kerbrat P, van Oosterom AT, Kerger J, Tursz T, van Glabbeke M, van Pottelsberghe C, et al.: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994;5(6):539-42.
20. Verweij J, Catimel G, Sulkes A, Sternberg C, Wolff I, Aamdal S, van Hoesel Q: Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1995;31A(suppl 4):S21-4.
21. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D, Judson IR: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18(10):2081-6.
22. Casper ES, Waltzman RJ, Schwartz GK, Sugarman A, Pfister D, Ilson D, Woodruff J, Leung D, Bertino JR: Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 1998;16(7):442-6.
23. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, Schwartz GK, Casper ES: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86(10):2034-7.
24. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20(12):2824-31.
25. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13(3):176-81.
26. Buesa JM, Losa R, Fernandez A, Sierra M, Esteban E, Diaz A, Lopez-Pousa A, Fra J: Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer 2004;101(10):2261-9.
27. Wall N, Starkhammar H: Chemotherapy of soft tissue sarcoma - a clinical evaluation of treatment over ten years. Acta Oncol 2003;42(1):55-61.
28. Hartmann JT, Mayer F, Schleicher J, Horger M, Huober J, Meisinger I, Pintoffl J, Kafer G, Kanz L, Grunwald V: Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a non-comparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007;110(4):861-6.
29. Huygh G, Clement PM, Dumez H, Schoffski P, Wildiers H, Selleslach J, Jimeno JM, Wever ID, Sciot R, Duck L, Van Oosterom AT: Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 2006;2006:56282.
30. Look KY, Sandler A, Blessing JA, Lucci JA 3rd, Rose PG: Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 2004;92(2):644-7.
31. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002;94(12):3225-9.
32. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22(9):1706-12.
33. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research through Collaboration Study 002 [corrected]. J Clin Oncol 2007;25(19):2755-63.
34. Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Blay JY: Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006;119(3):706-11.
35. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364(9440):1127-34.
36. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32.
37. Fox E, Curt GA, Balis FM: Clinical trial design for target-based therapy. Oncologist 2002;7(5):401-9.
38. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC: Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001;19(1):265-72.
39. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17(1):150-7.